Dialysis-Related Amyloidosis Treatment Act of 2025

# Dialysis-Related Amyloidosis Treatment Act of 2025 - Summary **What the Bill Does:** This bill addresses dialysis-related amyloidosis (DRA), a serious condition that develops in patients undergoing long-term dialysis treatment for kidney failure. The bill aims to improve treatment options and patient care for those affected by DRA, though the specific provisions aren't detailed in the available information. **Who It Affects:** The legislation primarily impacts dialysis patients—roughly 500,000 Americans with end-stage renal disease who depend on dialysis to filter waste from their blood. DRA occurs when abnormal protein accumulates in joints and tissues, causing pain and mobility problems.

The bill could also affect dialysis providers, manufacturers of dialysis equipment, and healthcare systems treating these patients. **Current Status:** The bill (HR 4055) was introduced in the 119th Congress by Representative Brian Babin (R-TX) and is currently in committee review. This means it hasn't yet advanced to a full House vote. Until it progresses further or detailed language becomes available, the specific provisions—such as funding mechanisms, coverage changes, or treatment requirements—remain unclear.